id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9365 R32754 |
Trivedi (Valproate) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.85 [0.28;2.56] C excluded (control group) |
23/322 4/48 | 27 | 322 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9366 R32755 |
Trivedi (Valproate) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 6.92 [1.70;28.18] | 23/322 5/178 | 28 | 322 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9367 R32756 |
Vajda (Valproate) (Controls exposed to Lamotrigine, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.86 [0.37;2.02] C excluded (control group) |
9/284 14/382 | 23 | 284 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9368 R32757 |
Vajda (Valproate) (Controls unexposed, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 5.39 [0.65;42.15] | 9/284 1/170 | 10 | 284 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9320 R32474 |
Miškov (Valproate) (Controls exposed to Lamotrigine, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.66 [0.03;13.98] C excluded (control group) |
0/6 4/37 | 4 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9321 R32478 |
Miškov (Valproate) (Controls unexposed, disease free), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
23.18 [0.42;1280.78] C excluded (control group) |
0/6 0/128 | 0 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9322 R32482 |
Miškov (Valproate) (Controls unexposed, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.64 [0.01;40.08] C | 0/6 0/4 | 0 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9282 R32197 |
Arkilo (Valproate), 2015 | Unsuccessful pregnancies (miscarriages/stillbirths) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.87 [0.09;91.05] C | 0/2 2/24 | 2 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9364 R32752 |
Tomson (Valproate), 2015 | Intrauterine death | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 1.18 [0.91;1.52] | 95/1,171 150/1,910 | 245 | 1,171 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9333 R32563 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Intrauterine death | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.25 [0.92;1.69] C | 76/1,290 105/2,198 | 181 | 1,290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9319 R32471 |
Meador (Valproate), 2006 | Fetal death (early and late intrauterine deaths) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 7.33 [0.35;155.16] C | 2/69 0/98 | 2 | 69 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 1.46 [1.01;2.11] | 468 | 3,144 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick; 2: Valproate) (Controls unexposed, sick; 3: Valproate) (Controls unexposed, sick; 4: Valproate; 5: Valproate; 6: Valproate) (Controls exposed to Lamotrigine, sick; 7: Valproate;
Asymetry test p-value = 0.0753 (by Egger's regression)
slope=0.0501 (0.1281); intercept=1.1048 (0.4933); t=2.2395; p=0.0753
excluded 9320, 9321, 9365, 9367